Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 07/25/24
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty SwallowingPRNewsWire • 07/18/24
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial ResultsPRNewsWire • 07/11/24
Neurocrine Biosciences: Diverse Pipeline, High Margins, And Growth Potential In BiotechSeeking Alpha • 07/11/24
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term GrowthSeeking Alpha • 07/09/24
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAHPRNewsWire • 07/01/24
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024PRNewsWire • 06/03/24
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicinePRNewsWire • 06/03/24
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicinePRNewsWire • 06/03/24
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024PRNewsWire • 05/28/24
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) CapsulesPRNewsWire • 05/21/24
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024PRNewsWire • 05/14/24
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024PRNewsWire • 05/09/24
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsPRNewsWire • 05/09/24
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsGlobeNewsWire • 05/09/24
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsPRNewsWire • 05/08/24
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care ConferencePRNewsWire • 05/07/24
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024PRNewsWire • 05/07/24
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and MonitoringPRNewsWire • 05/06/24